{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:36:11Z","timestamp":1794072971278,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2507802"],"award-info":[{"award-number":["2023YFC2507802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470136"],"award-info":[{"award-number":["82470136"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470138"],"award-info":[{"award-number":["82470138"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.rpth.2026.103460","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T03:57:57Z","timestamp":1774583877000},"page":"103460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The therapeutic landscape of inherited bleeding disorders in China"],"prefix":"10.1016","volume":"10","author":[{"given":"Yun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5947-3924","authenticated-orcid":false,"given":"Feng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7012-2420","authenticated-orcid":false,"given":"Man-Chiu","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3741-8518","authenticated-orcid":false,"given":"Renchi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.103460_bib1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/a-2681-4611","article-title":"Overview on rare congenital bleeding disorders and epidemiological data from the German Haemophilia Registry (DHR) and a survey in Germany, Austria, and Switzerland","volume":"45","author":"Holstein","year":"2025","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.rpth.2026.103460_bib2","first-page":"89","article-title":"[Consensus of Chinese expert on the diagnosis and treatment of rare bleeding disorders (version 2021)]","volume":"42","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.rpth.2026.103460_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.7326\/M19-1208","article-title":"Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries","volume":"171","author":"Iorio","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rpth.2026.103460_bib4","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/hae.14029","article-title":"Real-world analysis of haemophilia patients in China: a single centre\u2019s experience","volume":"26","author":"Song","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103460_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.lmd.2024.100007","article-title":"Report on the diagnosis and treatment of hemophilia in China (Version 2024)","volume":"1","author":"Xue","year":"2024","journal-title":"LabMed Discovery"},{"key":"10.1016\/j.rpth.2026.103460_bib6","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1007\/s12325-025-03151-5","article-title":"Disease burden and treatment patterns amongst patients with haemophilia A in China: a retrospective database analysis study","volume":"42","author":"Song","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.rpth.2026.103460_bib7","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1186\/s13023-025-04051-1","article-title":"Clinical, humanistic, and economic burden of haemophilia A in China: findings from a real-world survey","volume":"20","author":"Feng","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.rpth.2026.103460_bib8","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/hae.70041","article-title":"Clinical and economic burden of patients with haemophilia A and B in France: analysis of a nationwide claims database","volume":"31","author":"Frenzel","year":"2025","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103460_bib9","first-page":"681","article-title":"[Chinese guidelines on the treatment of hemophilia (2025)]","volume":"46","year":"2025","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.rpth.2026.103460_bib10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s13023-023-02835-x","article-title":"Treatment regimens, patient reported outcomes and health-related quality of life in children with moderate and severe hemophilia A in China: using real-world data","volume":"18","author":"Zhang","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.rpth.2026.103460_bib11","series-title":"Treatment Patterns and Disease Burden in Chinese Hemophilia Patients","year":"2024"},{"key":"10.1016\/j.rpth.2026.103460_bib12","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/hae.14350","article-title":"Pharmacokinetic, efficacy and safety evaluation of B-domain-deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A","volume":"27","author":"Xue","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103460_bib13","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1111\/hae.14622","article-title":"Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A","volume":"28","author":"Wu","year":"2022","journal-title":"Haemophilia"},{"issue":"suppl 2","key":"10.1016\/j.rpth.2026.103460_bib14","article-title":"PB0212 Evaluation of omfiloctocog alfa (SCT800) efficacy in real-world treatment of severe hemophilia A in China: insights from the SURPASS study [abstract]","volume":"8","author":"Xue","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103460_bib15","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1111\/hae.14652","article-title":"Efficacy, safety and bioequivalence of the human-derived B-domain-deleted recombinant factor VIII TQG202 for prophylaxis in severe haemophilia A patients","volume":"28","author":"Xi","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103460_bib16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/hae.14777","article-title":"Efficacy and safety of the B-domain-deleted TQG202 for on-demand treatment in moderate and severe haemophilia A patients: a multicentre, single-arm trial","volume":"29","author":"Sun","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103460_bib19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0140-6736(24)02139-1","article-title":"Haemophilia","volume":"405","author":"Chowdary","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2026.103460_bib20","first-page":"881","article-title":"[Chinese guidelines on the diagnosis and management of hemophilia with inhibitors (2023)]","volume":"44","year":"2023","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.rpth.2026.103460_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1046\/j.1538-7836.2003.00059.x","article-title":"A new approach to treatment of bleeding episodes in young hemophilia patients: a single bolus megadose of recombinant activated factor VII (NovoSeven)","volume":"1","author":"Kenet","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103460_bib23","author":"Liu"},{"key":"10.1016\/j.rpth.2026.103460_bib27","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/S2352-3026(22)00113-2","article-title":"Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial","volume":"9","author":"Xue","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2026.103460_bib28","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJMc2211173","article-title":"Total knee arthroplasty after gene therapy for hemophilia B","volume":"387","author":"Xue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2026.103460_bib29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41591-025-04012-y","article-title":"Factor IX-Padua AAV gene therapy in hemophilia B: phases 1\/2 and 3 trials","volume":"32","author":"Xue","year":"2026","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2026.103460_bib30","first-page":"34","article-title":"[Status and advances of long-acting factor \u2167]","volume":"34","author":"Lu","year":"2018","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"10.1016\/j.rpth.2026.103460_bib31","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.rpth.2026.103460_bib32","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood-2023-180649","volume":"142","author":"Xue","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103460_bib33","first-page":"2786","article-title":"First-in-human pharmacokinetic, safety, and preliminary efficacy studies of single- and multiple-dose FRSW117, a novel PEGylated recombinant factor VIII-Fc fusion protein with an extended half-life, in patients with severe hemophilia A","volume":"110","author":"Xue","year":"2025","journal-title":"Haematologica"},{"issue":"suppl 2","key":"10.1016\/j.rpth.2026.103460_bib34","article-title":"OC 40.1 A novel extended half-life factor VIII Fc fusion protein FRSW107 for severe hemophilia A: a multicentre, open-label, single-arm, phase 3 study and its open-label extension [abstract]","volume":"8","author":"Xue","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 2","key":"10.1016\/j.rpth.2026.103460_bib35","article-title":"OC 21.3 The in vitro and in vivo hemostatic efficacies of a novel FVIIIa-mimetic bispecific antibody, SS315, for the treatment of hemophilia A [abstract]","volume":"8","author":"Zhu","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 1","key":"10.1016\/j.rpth.2026.103460_bib36","doi-asserted-by":"crossref","first-page":"8474","DOI":"10.1182\/blood-2022-159948","article-title":"Factor X activator for hemophilia patients with inhibitors: a phase 1, first-in-human, multi-center, and open-label trial","volume":"140","author":"Liu","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.rpth.2026.103460_bib37","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood-2024-199149","article-title":"A specific coagulation factor X activator for on-demand treatment in hemophilia with inhibitors","volume":"144","author":"Liu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103460_bib38","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.jtha.2023.01.040","article-title":"Preclinical studies of a factor X activator and a phase 1 trial for hemophilia patients with inhibitors","volume":"21","author":"Liu","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"suppl 2","key":"10.1016\/j.rpth.2026.103460_bib39","article-title":"PB0242 A phase I trial evaluating safety and pharmacokinetics in human and an ex vivo pharmacodynamics study in hemophilia patients of KN057, the first anti\u2013TFPI monoclonal antibody in China [abstract]","volume":"8","author":"Feng","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"issue":"suppl 2","key":"10.1016\/j.rpth.2026.103460_bib40","article-title":"PB0875 Safety and efficacy of KN057 the first anti-TFPI monoclonal antibody in Chinese hemophilia patients [abstract]","volume":"9","author":"Ju","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.103460_bib41","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood.2023020005","article-title":"Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models","volume":"142","author":"Jiang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.103460_bib43","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/s41392-026-02599-3","article-title":"Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity","volume":"11","author":"Liu","year":"2026","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.rpth.2026.103460_bib44","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/hae.14101","article-title":"Haemophilia care in China: achievements in the past decade","volume":"26","author":"Dou","year":"2020","journal-title":"Haemophilia"},{"issue":"suppl 3","key":"10.1016\/j.rpth.2026.103460_bib45","first-page":"s525","article-title":"The European standards of Haemophilia Centres","volume":"12","author":"Giangrande","year":"2014","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2026.103460_bib46","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/hae.13425","article-title":"Principles of haemophilia care: the Asia-Pacific perspective","volume":"24","author":"Dunkley","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103460_bib47","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1111\/hae.14878","article-title":"A national assessment of standards of care for inherited bleeding disorders in Canada","volume":"29","author":"Page","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103460_bib48","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/hae.14887","article-title":"Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy","volume":"29","author":"Boban","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.103460_bib49","first-page":"281","article-title":"[Keeping up with the trends and improving the hierarchical system for the diagnosis and treatment of hemophilia in China]","volume":"46","author":"Yang","year":"2025","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.rpth.2026.103460_bib50","first-page":"1","article-title":"Standard for he establishment of hemophilia center (Version 2024)","volume":"30","year":"2024","journal-title":"Chinese Journal of Thrombosis and Hemostasis"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926001184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926001184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:18:14Z","timestamp":1790723894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926001184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2475037926001184"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103460","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The therapeutic landscape of inherited bleeding disorders in China","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.103460","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103460"}}